Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.
Di Nicola M
Hum Gene Ther. 14(14):1347-60.
CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C
Bone Marrow Transplant. 21(6):561-8.
Clonogenic capacity and ex vivo expansion potential of umbilical cord blood progenitor cells are not impaired by cryopreservation.
Almici C
Bone Marrow Transplant. 19(11):1079-84.
Clinical relevance of two in vitro tests based on CFU-GM assay in the study of granulopoietic failure.
Carlo Stella C
Haematologica. 70(6):487-94.
Cell- and humoral-mediated granulopoietic failure detected by CFU-GM assay in one case of Felty’s syndrome unresponsive to prednisolone treatment.
Carlo Stella C
Haematologica. 70(4):296-302.
Circulating granulocytic progenitor cell (CFU-GM) cultures in a long surviving case of smouldering leukemia.
Bobbio Pallavicini E
Haematologica. 69(6):687-94.
Chromatin connectivity maps reveal dynamic promoter-enhancer long-range associations.
Zhang Y
Nature. 2013 Nov 10;504(7479):306-310. doi: 10.1038/nature12716
Clinical and biological implications of driver mutations in myelodysplastic syndromes.
Papaemmanuil E
Blood. 2013 Sep 12;122(22):3616-27; quiz 3699. doi: 10.1182/blood-2013-08-518886
Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation.
Della Porta MG
J Clin Oncol. 34(30):3627-3637. doi: 10.1200/JCO.2016.67.3616
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Passamonti F
Lancet Haematol. 2020 Aug 13;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9